ViruCure Therapeutics

Oncolytic Virus-based Technology Platform for Treating Cancer

Health Tech & Life Sciences
Non Active, Dec 2024 ceased to operate

Company Overview

Snapshot

Founded in September 2016 by Yoram Drucker and Shay Tayeb, ViruCure Therapeutics operated with 1–10 employees. The company secured one funding round from one investor, reaching the Seed stage. The company ceased operations in December 2024.

Business overview

ViruCure Therapeutics is a biotechnology company focused on developing NADAV, an oncolytic Newcastle disease virus (NDV) platform designed for treating various cancer types. The NADAV technology leverages the selective, replicative, and safe oncolytic effect of NDV in humans, specifically targeting cancerous cells to replicate and infect other nearby and distal cancerous cells. This process induces cell death and triggers the host's immune response against tumors, with low toxicity due to its specific action on tumor cells. The initial targeted therapies for this platform were glioblastoma multiforme and lung cancer patients. The proprietary NDV technology was developed at the Hebrew University of Jerusalem, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Company Intelligence Q&A

What is ViruCure Therapeutics' primary focus?
ViruCure Therapeutics develops NADAV, an oncolytic Newcastle disease virus (NDV) platform for treating a wide range of cancer types, focusing on its selective, replicative, and safe oncolytic effect in humans.
When was ViruCure Therapeutics founded and by whom?
ViruCure Therapeutics was founded in September 2016 by Yoram Drucker and Shay Tayeb.
What is the core technology behind ViruCure Therapeutics' platform?
The core technology is NADAV, a proprietary Newcastle disease virus (NDV) strain that specifically targets and replicates within cancerous cells, causing cell death and activating the host's anti-tumoral immune response with low toxicity.
Which cancer types are initially targeted by the NADAV platform?
The initial targeted therapies for the NADAV platform are glioblastoma multiforme and lung cancer patients.
What is the current operational status of ViruCure Therapeutics?
ViruCure Therapeutics is currently non-active and ceased to operate in December 2024.

External links